Optimizing outcomes in implantology: the role of dexamethasone

The management of postoperative sequelae — pain, edema, and trismus — remains a major challenge in oral implantology, directly impacting clinical recovery and patient satisfaction. This systematic analysis, based on evidence-based data published between 2013 and 2024 (from PubMed, Scopus, Cochrane, and Google Scholar), evaluates the efficacy and safety of dexamethasone as a component of perioperative pharmacological support.

The specific objective of this study is to synthesise the impact of different dosages (from 1 to 8 mg) and various administration routes (oral, intramuscular, intravenous, submucosal, and topical) on visual analogue scale (VAS) scores, swelling volume, and the degree of trismus after implant placement.

The authors test the hypothesis that preventive administration of dexamethasone allows for a significant reduction in inflammatory symptoms without compromising osteogenesis processes. The study also examines the drug's safety profile, focusing on the frequency of adverse events, particularly in patients with comorbidities such as diabetes mellitus.

Methodology of the systematic analysis

The authors of this review performed a systematic analysis of clinical evidence published over an 11-year period, between 2013 and 2024. The literature search was rigorously conducted via four major scientific databases: PubMed, Scopus, Cochrane Library, and Google Scholar.

The protocol targeted the evaluation of the efficacy and safety of dexamethasone specifically within the framework of the perioperative management of dental implant placement. The researchers compiled and analyzed the following parameters:

• Therapeutic regimens: Various dosages from 1 to 8 mg.
• Administration protocols: Comparison of oral, intramuscular (IM), intravenous (IV), submucosal, and topical routes.
• Clinical follow-up indicators: Pain score by visual analogue scale (VAS), measurement of edema volume and evaluation of the degree of trismus.
• Safety profile: Recording the frequency of adverse events.

The analysis also integrates specific Ukrainian clinical data to validate the feasibility of short treatment regimens and to verify the absence of interference with peri-implant osteogenesis processes.

Clinical impact and efficacy of dexamethasone

The authors of this systematic analysis, having compiled data from international research databases (2013–2024), report a significant improvement in postoperative outcomes through the use of dexamethasone. The results show a marked reduction in post-implant inflammatory symptoms.

The analysis specifies that the maximum effect is achieved with preoperative administration, ideally 30 to 60 minutes before the surgical procedure. Although the study examined dosages ranging from 1 to 8 mg, a single dose of 4 mg is identified as optimal for the majority of patients in routine practice.

Comparison of protocols and administration routes

The review evaluated several routes of administration: oral, intramuscular, intravenous, submucosal, and topical. The compiled data indicate that:

• Les dosages de 4 à 8 mg en préopératoire offrent la meilleure cinétique d'action pour prévenir l'inflammation.
• Local submucosal administration is an effective alternative to systemic routes for reducing immediate sequelae.
• The Ukrainian clinical data integrated into the analysis confirm the feasibility of these short protocols without negative impact on peri-implant osteogenesis.

Safety profile and qualitative observations

In terms of safety, the authors report a particularly low frequency of adverse events, estimated between 3 and 5% of cases. These events are qualified as minor and manifest mainly as transient hyperglycemia, observed specifically in patients with type 2 diabetes.

From a qualitative perspective, the study highlights that dexamethasone acts as an essential pathogenic component of pharmacological support in implantology, promoting faster recovery without compromising the osseous integration of the implants.

Analysis of results: a major clinical lever

The data compiled in this systematic review (2013-2024) confirms that the use of dexamethasone is not a luxury, but a pillar of perioperative management. The authors report impressive objective reductions: a 30 to 45% decrease in pain and a 25 to 43% reduction in oedema. For the practitioner, these figures translate into a significant reduction in post-implantology emergency calls and better overall patient acceptance of the treatment.

The most interesting aspect lies in the administration window. The synthesis shows that efficacy is maximal with a preventive dose of 4 to 8 mg administered 30 to 60 minutes before the surgical procedure. The fact that a single 4 mg dose is considered optimal for the majority of cases considerably simplifies the office protocol, while limiting systemic risks.

Limits and safety: a favorable benefit-risk profile

Although the review highlights high safety with only 3 to 5% of adverse effects, particular vigilance remains necessary for diabetic patients due to the observed transient hyperglycemia. The key strength of this analysis is to reassure regarding the absence of negative impact on osteogenesis, a fear often expressed by implantologists when faced with corticosteroids.

However, the authors emphasize the need for multicenter randomized clinical trials to definitively standardize these protocols. In the meantime, current data validate dexamethasone as an essential pathogenic component of pharmacological support in dental implantology.

The essentials of the study

This systematic literature review (2013-2024) demonstrates that dexamethasone reduces postoperative pain intensity by 30 to 45%, oedema by 25 to 43%, and trismus by approximately 30% during dental implant placement. The authors report that maximum efficacy is achieved with a preoperative administration of 4 to 8 mg, while noting excellent safety with only 3 to 5% of minor adverse effects.

Dexamethasone and dental implantation: the optimal protocol finally clarified

Managing postoperative outcomes in implantology remains a daily challenge: pain, edema, and trismus directly impact patient satisfaction and healing kinetics. This systematic literature review, covering the 2013-2024 period and based on PubMed, Scopus, and Cochrane databases, provides quantified answers on the use of dexamethasone.

Measurable clinical efficacy

The data compiled by the authors reveal that the use of dexamethasone allows for a significant reduction in postoperative sequelae. Pain, assessed via the Visual Analogue Scale (VAS), drops by 30% to 45%. Oedema is reduced by 25% to 43%, while trismus decreases by approximately 30%. These figures are not merely statistical; they represent a major gain in patient comfort within the first 24 hours.

Timing and dosage: a consensus is emerging

Analysis of the various protocols (dosages from 1 to 8 mg and varied administration routes: oral, intramuscular, intravenous, submucosal, or topical) shows a superiority of preventive protocols. The maximum effect is observed with a preoperative administration of 4 to 8 mg, ideally 30 to 60 minutes before the surgical procedure. This preemptive approach allows for the saturation of glucocorticoid receptors before the peak release of inflammatory mediators.

Security and impact on osteogenesis

A persistent concern involves the effect of corticosteroids on bone regeneration. The clinical data analyzed, notably from Ukraine, confirm that short-term dexamethasone therapeutic regimens have no negative impact on osteogenesis. Regarding safety, adverse effects remain minor (3% to 5% of cases), manifesting mainly as transient hyperglycemia in diabetic patients. Caution therefore remains necessary for this specific population, without contraindicating short-term use.

Conclusion

Dexamethasone stands out as a pillar of the pharmacological arsenal in implantology. Its ability to modulate the inflammatory response without compromising hard tissues makes it a rational choice for standardizing postoperative outcomes.

In practical terms, for the practitioner:

• Favor a single 4 mg preoperative dose (30-60 min before incision) for the majority of standard cases.
• Consider increasing to 8 mg for more invasive surgeries (sinus lift, complex grafts).
• Carefully monitor blood glucose levels in your diabetic patients, as the primary risk is transient post-administration hyperglycemia.

Information intended for healthcare professionals. This content may contain errors or truncated summaries. We recommend always verifying with the original source article. Delynov disclaims all responsibility regarding the use of this information. This document is not intended for patients or the general public.